MDXG Q3 2022 Earnings — MiMedx Group, Inc. Revenue & Financial Results | Market Cap Arena

MDXGMiMedx Group, Inc.

$684M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$68M+7.3% YoY

Gross Profit

$56M82.0% margin

Operating Income

-$7M-10.5% margin

Net Income

-$8M-12.4% margin

EPS (Diluted)

$-0.07

QoQ Revenue Growth

+1.2%

Cash Flow

Operating Cash Flow

$959,000

Free Cash Flow

$610,000

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$173M

Total Liabilities

$100M

Stockholders' Equity

$73M

Cash & Equivalents

$73M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$68M	$63M	+7.3%
Gross Profit	$56M	$53M	+4.8%
Operating Income	-$7M	-$1M	-560.7%
Net Income	-$8M	-$2M	-260.2%

Revenue Segments

Advanced Wound Care

$67M50%

Advanced Wound Care, Tissue And Other

$61M46%

Advanced Wound Care, Umbilical Cord-Derived

$6M4%

Product and Service, Other

$84,0000%